Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2022 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to...
July 12, 2022 16:05 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
July 05, 2022 07:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
May 04, 2022 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering

NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
January 04, 2022 05:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Provides Clinical and Corporate Update

ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety...
November 15, 2021 16:05 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop...
November 10, 2021 16:05 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track...
November 03, 2021 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease

- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract - - Patients with gout and CKD have a serious condition with an unmet need for urate-lowering–therapies – ...
September 29, 2021 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease - - Novel therapeutic candidate targets uric acid in the GI tract - - Initial data...
September 09, 2021 08:30 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop...